Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of “Moderate Buy” from Analysts

Perspective Therapeutics, Inc. (NYSE:CATX) has earned an average rating of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $15.14.

A number of equities analysts recently issued reports on CATX shares. Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $24.00 to $5.00 in a research note on Monday, November 25th. Wedbush restated an “outperform” rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research note on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. UBS Group began coverage on Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Oppenheimer reduced their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research note on Friday, November 22nd.

Insider Activity at Perspective Therapeutics

In other news, Director Heidi Henson purchased 25,975 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were bought at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the completion of the purchase, the director now directly owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Jonathan Robert Hunt purchased 12,829 shares of the firm’s stock in a transaction on Monday, November 25th. The shares were purchased at an average price of $3.82 per share, for a total transaction of $49,006.78. Following the completion of the purchase, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at $186,416. This represents a 35.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 67,570 shares of company stock worth $256,789. Insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

A number of large investors have recently modified their holdings of CATX. FMR LLC boosted its stake in Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares in the last quarter. Janus Henderson Group PLC raised its stake in Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after acquiring an additional 355,685 shares during the last quarter. State Street Corp lifted its position in Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after acquiring an additional 1,192,812 shares during the period. Nicholson Wealth Management Group LLC purchased a new position in shares of Perspective Therapeutics in the 3rd quarter valued at approximately $21,390,000. Finally, Geode Capital Management LLC increased its holdings in shares of Perspective Therapeutics by 12.5% in the third quarter. Geode Capital Management LLC now owns 1,164,204 shares of the company’s stock valued at $15,546,000 after purchasing an additional 129,654 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $3.63 on Friday. The business has a fifty day moving average of $3.87 and a two-hundred day moving average of $9.85. Perspective Therapeutics has a twelve month low of $2.70 and a twelve month high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The firm had revenue of $0.37 million during the quarter. On average, equities analysts forecast that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.